Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin/Glimepiride FDC in T2DM
NCT02089126Phase 3Unknown
- Sponsor
- LG Chem
- Start
- Jun 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Gemigliptin/Glimepiride combination with Placebo (2 arms). Primary endpoint: HbA1c Changes at 24 weeks. Status: unknown.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02089126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089126.